Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.

Section of Stem Cell Biology, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
Blood (Impact Factor: 9.78). 12/2010; 117(8):2460-8. DOI: 10.1182/blood-2010-08-300087
Source: PubMed

ABSTRACT RARA (retinoic acid receptor alpha) haploinsufficiency is an invariable consequence of t(15;17)(q22;q21) translocations in acute promyelocytic leukemia (APL). Retinoids and RARA activity have been implicated in hematopoietic self-renewal and neutrophil maturation. We and others therefore predicted that RARA haploinsufficiency would contribute to APL pathogenesis. To test this hypothesis, we crossed Rara(+/-) mice with mice expressing PML (promyelocytic leukemia)-RARA from the cathepsin G locus (mCG-PR). We found that Rara haploinsufficiency cooperated with PML-RARA, but only modestly influenced the preleukemic and leukemic phenotype. Bone marrow from mCG-PR(+/-) × Rara(+/-) mice had decreased numbers of mature myeloid cells, increased ex vivo myeloid cell proliferation, and increased competitive advantage after transplantation. Rara haploinsufficiency did not alter mCG-PR-dependent leukemic latency or penetrance, but did influence the distribution of leukemic cells; leukemia in mCG-PR(+/-) × Rara(+/-) mice presented more commonly with low to normal white blood cell counts and with myeloid infiltration of lymph nodes. APL cells from these mice were responsive to all-trans retinoic acid and had virtually no differences in expression profiling compared with tumors arising in mCG-PR(+/-) × Rara(+/+) mice. These data show that Rara haploinsufficiency (like Pml haploinsufficiency and RARA-PML) can cooperate with PML-RARA to influence the pathogenesis of APL in mice, but that PML-RARA is the t(15;17) disease-initiating mutation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Advancements in sequencing techniques have led to the discovery of numerous genes not previously implicated in acute myeloid leukemia (AML) biology. Further in vivo studies are necessary to discern the biological impact of these mutations. Murine models, the most commonly used in vivo system, provide a physiologic context for the study of specific genes. These systems have provided deep insights into the role of genetic translocations, mutations, and dysregulated gene expression on leukemia pathogenesis. This review focuses on the phenotype of newly identified genes, including NPM1, IDH1/2, TET2, MLL, DNMT3A, EZH2, EED, and ASXL1, in mouse models and the implications on AML biology.
    Seminars in Hematology 10/2014; 51(4). DOI:10.1053/j.seminhematol.2014.08.005 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore performed a phase I study of combination bexarotene and decitabine in elderly and relapsed AML patients. We found that this combination was well tolerated, although outcomes were modest (1 CRi, and 3 PR among 19 patients). Correlative studies found that patients with clinical response had increased differentiation to bexarotene both in vivo and ex vivo, suggesting that pre-treatment analysis might identify a more susceptible subgroup of patients.
    American Journal of Hematology 08/2014; 89(8). DOI:10.1002/ajh.23735 · 3.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ideal in vivo models for studies of leukemia pathogenesis and treatment would have several important features. First, these animals would have phenotypes that are robust and reproducible. Second, these models would reliably develop phenotypes that accurately recapitulate disease observed in the clinic with short latency and high penetrance sufficient for informative preclinical therapeutic studies. Leukemia models based on retroviral transduction of oncogenes followed by transplantation into irradiated syngeneic hosts offer a rapid and cost-efficient way to evaluate the effects of a gene or mutation of interest but in some cases result in inconsistent phenotypes due to non-physiological levels of expression and random genomic integration. Xenotransplantation models enable the propagation and analysis of primary human samples but may be difficult to interpret due to variability of genetic background, the effects of immune recognition, a limited knowledge of genetic alterations in samples before and after xenotransplantation, and incomplete interaction with the microenvironment. Genetically engineered mice represent tractable models of human myeloid malignancies, and in many cases empower the study of the molecular pathogenesis of leukemia and evaluation of novel chemotherapeutics. Our understanding of the molecular pathogenesis of myeloid malignancies relies largely on the knowledge of cytogenetic abnormalities and recurrent chromosomal translocations, many of which have been successfully modeled in laboratory animals. In addition, as our knowledge of the genetics of myeloid leukemia improves with additional integrated profiling efforts, it will lead to more accurate animal models and facilitate translational efforts in the leukemia field. Here we review the most recent advances in the generation of mouse models of myeloid leukemias.
    Seminars in Hematology 04/2013; 50(2):145-55. DOI:10.1053/j.seminhematol.2013.03.027 · 2.46 Impact Factor